Personalized Health & Prevention
115 views | +0 today
Follow
Personalized Health & Prevention
ZdravMedInfo - Daily Medical & Biomedical News and Information Aggregator from Best Med Infosources (RUS/ENG):
http://www.zdravmedinfo.ru, https://www.rebelmouse.com/ZdravMedInfo,
Personalized Health & Prevention News Digest: https://www.rebelmouse.com/ZdravMedInfo/Preventive_Medicine/
Curated by ZdravMedInfo
Your new post is loading...
Your new post is loading...
Scooped by ZdravMedInfo
Scoop.it!

Personalized Health & Prevention News Board on ZdravMedInfo's Site

Personalized Health & Prevention  News Board on ZdravMedInfo's Site | Personalized Health & Prevention | Scoop.it

Source: https://www.rebelmouse.com/ZdravMedInfo/Preventive_Medicine/

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Ernst & Young | Beyond Borders: Biotechnology Industry Report 2013

more...
No comment yet.
Rescooped by ZdravMedInfo from Longevity science
Scoop.it!

Delayed aging is better investment than cancer, heart disease research, says study | KurzweilAI

Delayed aging is better investment than cancer, heart disease research, says study | KurzweilAI | Personalized Health & Prevention | Scoop.it

A new multi-university study shows that research to delay aging and the infirmities of old age would have better population health and economic returns than advances in individual fatal diseases such as cancer or heart disease.


With even modest gains in our scientific understanding of how to slow the aging process, an additional 5 percent of adults over the age of 65 would be healthy rather than disabled every year from 2030 to 2060, revealed the study in the October issue of Health Affairs.

 

Read more:

http://www.kurzweilai.net/delayed-aging-is-better-investment-than-cancer-heart-disease-research-says-study

 

 


Via Ray and Terry's
more...
Steve Kingsley's curator insight, October 9, 2013 8:40 PM

Sounds like common sense to me.

Rescooped by ZdravMedInfo from NanoMedicine Revolution
Scoop.it!

BBC Secret Universe: The Hidden Life of the Cell

This will help you to understand how a cell works.


Via Luís Bastos
more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Immunocore's T-cell therapy against cancer

Immunocore's T-cell therapy against cancer | Personalized Health & Prevention | Scoop.it

Using the body's immune system to fight cancer is one of the most promising areas of therapy, and could prove particularly helpful in the treatment of metastatic disease, when the cancer has spread from its original site...

Immunocore is probably the only company in the world that has developed a way of harnessing the power of the immune system's natural-born killer cells: the T-cells of the blood...

Immunocore has found a way of designing small protein molecules, which it calls ImmTACs, that effectively act as double-ended glue. At one end they stick to cancer cells, strongly and very specifically, leaving healthy cells untouched. At the other end they stick to T-cells.

The technology is based on the "T-cell receptor", the protein that sticks out of the surface of the T-cell and binds to its enemy target. Immunocore's ImmTACs are effectively independent T-cell receptors that are "bispecific", meaning they bind strongly to cancer cells at one end, and T-cells at the other – so introducing cancer cells to their nemesis...

The key to the success of the technique is being able to distinguish between a cancer cell and a normal, healthy cell. Immunocore's drug does this by recognising small proteins or peptides that stick out from the surface membrane of cancer cells. All cells extrude peptides on their membranes and these peptides act like a shop window, telling scientists what is going on within the cell, and whether it is cancerous or not.

 

Read more:

http://www.independent.co.uk/news/science/exclusive-cancer--a-cure-just-got-closer-thanks-to-a-tiny-british-company--and-the-result-could-change-lives-of-millions-8707590.html

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

U.S. Preventive Medicine - The Prevention Plan

U.S. Preventive Medicine - The Prevention Plan | Personalized Health & Prevention | Scoop.it

U.S. Preventive Medicine, Inc. (USPM) has created an innovative information technology solution for a personalized prevention program. 

 USPM’s The Prevention Plan is based on the clinical practice of preventive medicine with engagement in primary, secondary and tertiary prevention.  Users complete a health risk appraisal, receive virtual coaching, live coaching and social challenges to reduce their risks, participating at self-determined levels of engagement.           

The two-year study, “The Association of Technology in a Workplace Wellness Program with Health Risk Factor Reduction,” recently published in the Journal of Occupational and Environmental Medicine (March 2013), concludes that active Prevention Plan participants show significant improvements in health risk reduction. The study proves the relationship between level of engagement in workplace wellness programs and health risk reduction. Engaging technology and interactive Web-based tools can empower individuals to be more proactive about their health and reduce their health risks.

 

Read more: http://ccavoice.wordpress.com/2013/06/20/u-s-preventive-medicine-cca-members-employee-wellness-showcase/

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

EMERGING TRENDS IN BIOMEDICINE AND HEALTH TECHNOLOGY INNOVATION: ADDRESSING THE GLOBAL CHALLENGE OF ALZHEIMER'S

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Biomedicine, a trillion dollar U.S. business

Biomedicine’s star is rising as a significant growth sector in the U.S. economy, providing evidence that advocates are using to encourage government investment.

A report published by the science advocacy group United for Medical Research revised upward its calculations on how much payback research provides the U.S. economy and found that the industry is now a trillion dollar business.

A private analyst group called Battelle Technology Partnership Practice prepared the report on behalf of United for Medical Research (UMR). UMR is a coalition of universities, as well as cancer, diabetes, and heart disease foundations. It encourages government investment into the study of genomics, and suggests that continued funding of National Institutes of Health will revolutionize medicine.

 

Source: http://www.unitedformedicalresearch.com/wp-content/uploads/2013/06/The-Impact-of-Genomics-on-the-US-Economy.pdf

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Diagnoplex: Fighting Cancer Earlier with Colox

Diagnoplex: Fighting Cancer Earlier with Colox | Personalized Health & Prevention | Scoop.it

Diagnoplex’s colorectal cancer screening test, Colox®, combines 29 selected biomarkers with innovative and powerful statistical tools designed to answer this crucial question: “Should this ‘at risk’ individual undergo a colonoscopy?”

Although still in development, we believe that Colox® has the potential to become the leading primary screening test for asymptomatic people ‘at risk’ of colorectal cancer. Individuals testing positive with Colox® can be referred for colonoscopy, where polyps or lesions can be removed endoscopically and Stage I to Stage IV disease can be managed proactively.

Colox® will consist of a medical laboratory kit containing all the reagents necessary to perform the Colox® test in a routine and high-throughput laboratory setting. Kits and reagents will be compatible with commonly used instruments (sample preparation and PCR instruments) and kit components and workflow will conform to medical laboratory requirements.

Based on our pilot validation studies, Colox® has shown a significant number of benefits:

It accurately and reliably detects both pre-cancerous and early stage (stages I and II) colorectal cancer,It is organ and disease specific,It is minimally-invasive with no need for bowel or stool preparation,It can be performed during a routine medical and laboratory check-up,It is highly automated, scalable and cost-effective.

Diagnoplex is steadfast in its commitment to produce only the highest-quality technologies and devices that provide meaningful solutions for unmet medical needs. Strict application of the Colox® design control process has allowed Diagnoplex to successfully bring Colox® to the final stages of development with product and system requirements and final reagents and protocols in place.

 

***/

Diagnoplex Receives $1.4M from Investors to Support Colon Cancer Test - http://www.genomeweb.com/pcrsample-prep/diagnoplex-receives-14m-investors-support-colon-cancer-test
more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Genecopoeia

Genecopoeia | Personalized Health & Prevention | Scoop.it

GeneCopoeia, Inc. is a US-based manufacturer and provider of genomics and proteomics products and services for academic and governmental research institutes, pharmaceutical and biotechnology industry. Together with investors in China, GeneCopoeia formed a joint venture, FulenGen Co., Ltd. in P.R. China, which has been in operation since year 2000.

 

GeneCopoeia, Inc. offers gene and protein based products and services including full length ORF cDNA clones, recombinant proteins, RNAi products, custom cloning and more.

GeneCopoeia and its joint venture, FulenGen, have manufactured and released into market the largest number of human full length protein coding ORF cDNA clones in multiple sets of vector systems with various features which make these clones suitable for a variety of functional assays, protein expression and easy purification in many cell types as well as cell free transcription and translation coupling systems, and large scale functional genomics and proteomics studies. They also offer a comprehensive suite of accurate, reliable and affordable gene and protein based products and services that are integrated with our large collection of full length ORF cDNA clones, which includes recombinant proteins, polyclonal and monoclonal antibodies, RNAi products, custom cloning and protein production services, and other life sciences tools and products.


http://www.genecopoeia.com

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Personal Genomic Tests May Offer a Teachable Moment

Personal Genomic Tests May Offer a Teachable Moment | Personalized Health & Prevention | Scoop.it

Personal genomic tests are now widely available and sold directly to consumers, but population-based data are limited on awareness, use and impact of these tests.

So what can people who undertake personal genomic testing to improve health and prevent disease do with this information?  

First, we encourage consumers to have a healthy dose of skepticism about the interpretation of the findings, their probabilistic nature, and their utility for improving their health. With the exception of a few rare genetic variants, the interpretation of the test findings, especially the numbers reflecting individual risk of developing diseases should be viewed cautiously.

Second, we encourage consumers to discuss and share the results of tests with their health care providers, especially in the case of reported mutations with high risk for certain genetic conditions or carrier state for these conditions.

Third, regardless of what is in the genetic test result, we encourage consumers to seek, collect and validate as much as possible their family health history. The interpretation of genetic risks, especially for rare genetic conditions, could be highly dependent on the presence or absence of family history of certain diseases.

Fourth, there are general disease prevention and health promotion messages that are important, regardless of one’s genetic risk profile, including smoking cessation, physical activity, diet, vaccinations, injury prevention, and infectious disease control.

Finally, personal genomic tests can offer a unique process for consumers to use a “genomics lens” to learn about determinants of health and disease and to enhance both family and patient-provider interactions. By educating ourselves about the evolving knowledge of genomic and environmental determinants of common diseases and the current limitations of genomics, we can take charge of our own health, broaden our knowledge base, and continuously seek reliable and credible sources of health related information in the midst of tremendous background noise, unsubstantiated claims and rapidly changing science.

 

Read more: http://blogs.cdc.gov/genomics/2012/07/26/think-after-you-spit/

 


more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer

U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer | Personalized Health & Prevention | Scoop.it

The U.K. is piloting a new genetic test developed by Illumina Inc. to help cancer patients and their doctors better identify appropriate treatments and help determine if relatives have cancer risk.

Illumina’s TruSight test, to be introduced in 2014 at the Royal Marsden hospitals in London and Sutton, can analyze 97 genes that are linked to cancer within a few weeks for a few hundred dollars. The pilot program will start for women with breast and ovarian cancer and may eventually be rolled out to the rest of the U.K. National Health Service and for other types of cancers.


Read more: http://www.bloomberg.com/news/2013-05-20/u-k-to-pilot-illumina-genetic-test-for-breast-ovarian-cancer.html


From Illumina's site - http://www.illumina.com/applications/cancer.ilmn

 Solving the Cancer Puzzle with Next-Generation Sequencing and Microarrays - http://www.illumina.com/Documents/applications/cancer/app_spotlight_cancer.pdf
more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Topol on the Cancer Clinic of the Future

Dr. Eric Topol, director of the Scripps Translational Science Institute and Editor-in-Chief of Medscape, explains how the cancer clinic of the future will look. For more from Dr. Eric Topol, visit Medscape: medscape.com/features/public/creative-de­struction-medicine


Source: http://www.youtube.com/watch?v=pgJH1qLMiGM

more...
No comment yet.
Rescooped by ZdravMedInfo from Longevity science
Scoop.it!

Interactive Bionic Man, featuring 14 novel biotechnologies

Interactive Bionic Man, featuring 14 novel biotechnologies | Personalized Health & Prevention | Scoop.it

The National Institute of Biomedical Imaging and Bioengineering has launched the “NIBIB Bionic Man”  (http://www.nibib.nih.gov/science-education/bionic-man), an interactive Web tool that showcases cutting-edge research in biotechnology.

 

The bionic man features 14 technologies currently being developed by NIBIB-supported researchers.

 

Read more:

http://www.kurzweilai.net/interactive-bionic-man-featuring-14-novel-biotechnologies ;


Via Ray and Terry's
more...
No comment yet.
Rescooped by ZdravMedInfo from NanoMedicine Revolution
Scoop.it!

Future of Medicine

Personalized genomics. Big Health Data. Dr. James Canton, CEO of the Institute for Global Futures forecasts the future of medicine. From genomics, diagnostics, personalized medicine, wellness, mobile health, nanotechnology, geomedicine--are some of the key trends shaping ourselves and our world. Creating a predictive big data analytic view of your health today and in the future.


Via Luís Bastos
more...
No comment yet.
Rescooped by ZdravMedInfo from NanoMedicine Revolution
Scoop.it!

Introduction to Cells

This is a newly revised 3 minute HD dramatic video choreographed to powerful music, which introduces the viewer to the wonder and miracle of cells.

Via Luís Bastos
ZdravMedInfo's insight:

Amazing!

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Biomarker Breakthroughs - Paper.li

Biomarker Breakthroughs - Paper.li | Personalized Health & Prevention | Scoop.it

Biomarker Breakthroughs, by RayBiotech, Inc.: Biomarker Discovery & Validation News

 

RayBiotech's mission is to provide cutting-edge array technologies for the discovery of disease-related protein biomarkers and key factors, the identification of new drug targets, and the advancement of personalized medicine.

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

How Machine Learning and Big Data Are Changing the Face of Biological Sciences

Until recently, the wet lab has been a crucial component of every biologist. Today's advances in the production of massive amounts of data and the creation of machine-learning algorithms for processing that data are changing the face of biological science—making it possible to do real science without a wet lab. David Heckerman shares several examples of how this transformation in the area of genomics is changing the pace of scientific breakthroughs.

 

Source: https://www.youtube.com/watch?v=-Q447inB6YQ

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Life Technologies Launches Compendia Oncomine NGS Power Tools for Cancer Researchers

Life Technologies Launches Compendia Oncomine NGS Power Tools for Cancer Researchers | Personalized Health & Prevention | Scoop.it

Life Technologies Corporation (NASDAQ: LIFE) recently announced the introduction of Oncomine® Next Gen Sequencing Power Tools, an analytics offering that will allow cancer researchers to explore results from in-depth analysis of next generation sequencing (NGS) data, including data from The Cancer Genome Atlas. In total, more than 4,500 paired tumor and samples have been analyzed to date.

Oncomine® NGS Power Tools constitutes a suite of software tools that enable cancer researchers to easily survey novel predicted driver mutations and gene fusions across all cancers and within two dozen specific cancers types, as well as explore simple summary analyses that integrate multiple types of gene and pathway aberrations with clinical data.

 Read more:  

http://biomarkercommons.org/biomarker-news/life-technologies-launches-compendia-oncomine-ngs-power-tools-for-cancer-researchers-discovers-novel-gene-fusions

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Supreme Court Says “Natural” Human Genes May Not Be Patented

Supreme Court Says “Natural” Human Genes May Not Be Patented | Personalized Health & Prevention | Scoop.it

The decision should reduce uncertainty in the field of molecular diagnostics.

The Supreme Court gave a mixed ruling on the issue of human gene patents on Thursday, deciding that while DNA found naturally cannot be patented, synthetically produced DNA can.

The ruling means that companies will no longer be able to patent a sequence that exactly matches a sequence found in nature. 

The court’s decision specifically relates to the question of whether one such company, Myriad Genetics, could patent the sequences of two genes, BRCA1 and BRCA2, that are related to the risk of breast and ovarian cancer. Recently, actress Angelina Jolie announced that she underwent a preventive double mastectomy after learning she carried risk mutations in BRCA1. Myriad had held exclusive rights to determine whether a woman carried certain genetic variants in these genes that would predispose her to those cancers. It charged some $3,000 for the test.

The court’s decision says that Myriad does not have an exclusive right to test for these variants because they are naturally occurring. However, it also says that if a researcher or lab technician isolates a non-natural version of the gene in question—something known as complementary DNA, or cDNA—that person or company does have the exclusive rights to that sequence.

The decision could help clarify the best claim strategies for companies developing diagnostic tests (see http://www.technologyreview.com/news/514116/questions-over-gene-patents-shake-diagnostics-industry/).

In drawing this line between naturally occurring DNA and cDNA, the court was trying to encourage innovation within the industry as well as products derived from nature.

 

Read more: http://www.technologyreview.com/news/516101/supreme-court-says-natural-human-genes-may-not-be-patented/

 

http://www.csmonitor.com/USA/Justice/2013/0613/Supreme-Court-rules-that-human-genes-cannot-be-patented-video,

 

http://www.denverpost.com/opinion/ci_23455750/gene-patent-decision-shaky-scientific-ground

 

http://www.sciencenews.org/view/generic/id/351049/description/The_gene_patenting_decision_from_a_plaintiffs_point_of_view

 

http://latinbusinesstoday.com/2013/06/under-the-u-s-supreme-court-natural-dna-cant-be-patented/

 

http://www.forbes.com/sites/scottgottlieb/2013/06/14/supreme-court-on-genetic-tests-making-a-bad-business-worse/

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Antibody engineering know-how

Antibody engineering know-how | Personalized Health & Prevention | Scoop.it

Antibodies are of enormous value to society as therapeutic and diagnostic agents. There are many scientists worldwide interested in producing their own novel engineered antibody based molecules as part of their research work.

Scientists from UCD Conway Institute and UCD Nanomedicine Centre have published an accessible instruction manual detailing how to make antigen binding molecules for molecular studies and translational research. This protocol published in the journal Nature Protocols describes the design and development of recombinant antigen-binding molecules from monoclonal antibodies through rapid identification and cloning of variable genes. Describing the work, Conway scientist Dr David O'Connell said, "The protocol is accessible for groups not specialised in this area, and allows them to carry out reverse engineering of functional, recombinant antigen-binding molecules from hybridomas within 50 working days. We are delighted with this publication and view it an endorsement by a prestigious scientific journal of our experience in the engineering of antibodies. It reflects our capabilities in antibody design, construction and characterisation that are made possible through the excellent infrastructure available on the university campus." This research reflects a successful collaboration between UCD scientists with CRO Genscript Inc. The team, which also includes Conway Fellow, Professor Gil Lee hopes to attract new collaborators with both industry and academia on foot of this work.

 

More information: Nat Protoc. 2013 May 16;8(6):1125-48. http://dx.doi.org/10.1038/nprot.2013.057. Epub 2013 May 16.

Source: http://medicalxpress.com/news/2013-06-antibody-know-how.html

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

An Integrative Proteomics and Interaction Network-Based Classifier for Prostate Cancer Diagnosis

An Integrative Proteomics and Interaction Network-Based Classifier for Prostate Cancer Diagnosis | Personalized Health & Prevention | Scoop.it

Early diagnosis of prostate cancer (PCa), which is a clinically heterogeneous-multifocal disease, is essential to improve the prognosis of patients. However, published PCa diagnostic markers share little overlap and are poorly validated using independent data. Therefore, we here developed an integrative proteomics and interaction network-based classifier by combining the differential protein expression with topological features of human protein interaction networks to enhance the ability of PCa diagnosis.


Read more: http://www.plosone.org/article/info:doi/10.1371/journal.pone.0063941 ;

more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

Announcing OncoSpire Genomics, a joint venture of Mayo Clinic and Cancer Genetics Inc. - Individualized Medicine Blog

Announcing OncoSpire Genomics, a joint venture of Mayo Clinic and Cancer Genetics Inc. - Individualized Medicine Blog | Personalized Health & Prevention | Scoop.it

A big week for Mayo Clinic and Individualized Medicine.

Mayo Clinic and Cancer Genetics Inc. have teamed teamed up to launch OncoSpire Genomics (http://oncospiregenomics.com), a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing.

The start-up company will be based in Rochester, Minn., and will focus on discovering and commercializing new biomarkers for cancer. Cancer Genetics has committed to contributing $2 million in capital in the first year, with the possibility of contributing up to $6 million during the next three years. Mayo will contribute in-kind with sequencing and laboratory resources, clinical and research expertise, and other operational resources. Mayo Medical Laboratories and Mayo Clinic's Department of Laboratory Medicine and Pathology (http://www.mayoclinic.org/labmed-pathology-rst/) will help bring OncoSpire discoveries to patients at Mayo Clinic and elsewhere.

A scientific review committee will identify projects within the Center for Individualized Medicine's Biomarker Discovery Program (http://mayoresearch.mayo.edu/center-for-individualized-medicine/biomarker-discovery-program.asp) for commercial development through OncoSpire. Initial focus areas will include hematological and urogenital cancers, and potentially other cancers, as selected by the scientific review committee.

Biomarkers help physicians and providers understand cancers (and many other conditions) within the individual patient. Blood sugar in diabetes care is a common example. As next-generation sequencing helps us unlock many mysteries of cancer, biomarkers will lead to better prognoses and directed therapies. In some cases, such as pre-cancerous polyps, biomarkers can help physicians screen for the likelihood for cancer before the disease ever materializes.

 

Source: http://individualizedmedicineblog.mayoclinic.org/discussion/announcing-oncospire-genomics-joint-venture-of-mayo-clinic-and-cancer-genetics-inc

 

Read full release: http://www.mayoclinic.org/news2013-rst/7478.html

 

Video about biomarkers: http://www.youtube.com/watch?feature=player_embedded&v=ugXUFHRZti8



more...
No comment yet.
Scooped by ZdravMedInfo
Scoop.it!

The Cancer Genome Atlas: The Genetic Basis of Cancer

This video is one in a series of videos from The Cancer Genome Atlas (TCGA) project, explaining TCGA's approach to determining the important genomic changes that lead to cancer. TCGA researchers, Drs. Richard Gibbs, Peter Laird, Stacey Gabriel and Neil Hayes, talk about the difference between a normal cell and cancer cell and how understanding the changes in DNA that cause cancer can help doctors develop better treatments. The Cancer Genome Atlas is a comprehensive and coordinated effort supported by the National Cancer Institute and the National Human Genome Research Institute to accelerate our understanding of the genetics of cancer using innovative genome analysis technologies. 

 

To learn more about The Genetic Basis of Cancer, please visit http://cancergenome.nih.gov/newsevents/multimedialibrary/videos/thegeneticbasisofcancer

 

Source: http://www.youtube.com/watch?v=mVTPySEjFWw

more...
No comment yet.